News & Events:DXCM

  On Tuesday, 540 companies set new 52-week lows. These stocks set new 52-week lows on Tuesday: Be sure to monitor Benzinga for the news traders need!

Dexcom In Talks To Acquire Insulet, Create a Giant In Diabetes Devices: Bloomberg

DexCom, Inc. (DXCM) today announced that Brice Bobzien, Senior Vice President, Finance, will present an update on the company at the Piper Sandler Ophthalmology and Diabetes Symposium on Wednesday, May 25, 2022 at 1:00 p.m.. Links to the webcasts will be available on the Dexcom Investor Relations website at investors.dexcom.com and will be archived there for future reference.

DexCom, Inc. (DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the following upcoming investor conferences: Links to the webcasts will be available on the Dexcom Investor Relations website at investors.dexcom.com and will be archived there for future reference.

Pulled from Benzinga Pro data, DexCom posted Q1 earnings of $97.30 million, an increase from Q4 of 601.55%. Sales dropped to $628.80 million, a 9.94% decrease between quarters. Earnings data without context is not clear and can difficult to base trading decisions on. It is important to keep in mind that ROIC evaluates past performance and is not used as a predictive tool.

DexCom has outperformed the market over the past 10 years by 32.66% on an annualized basis producing an average annual return of 44.4%. Currently, DexCom has a market capitalization of $39.95 billion. Buying $1000 In DXCM: If an investor had bought $1000 of DXCM stock 10 years ago, it would be worth $40,310.89 today based on a price of $407.14 for DXCM at the time of writing.

DexCom, Inc. (DXCM) has updated its first quarter 2022 earnings call due to technical difficulties with the conference call provider. To listen to the conference call, please dial 374-5140 or 400-0571 and use the confirmation number "41691074#" approximately five minutes prior to the start time.

DexCom reported its Q1 earnings results on Thursday, April 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement. DexCom missed estimated earnings by 38.46%, reporting an EPS of $0.32 versus an estimate of $0.52. Revenue was up $123.80 million from the same period last year.

Dexcom Inc (DXCM): * DEXCOM REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS. * Q1 NON-GAAP EARNINGS PER SHARE $0.32. * Q1 GAAP EARNINGS PER SHARE $0.93. * SEES FY REVENUE ABOUT $2.82 BILLION TO $2.94 BILLION. * Q1 REVENUE ROSE 25 PERCENT TO $628.8 MILLION. * REITERATING GUIDANCE FOR FISCAL YEAR 2022.

DexCom, Inc. (DXCM) today reported its financial results as of and for the quarter ended March 31, 2022. First Quarter 2022 Financial Highlights: Strategic Highlights: “Dexcom (DXCM) is off to a great start in 2022, advancing a number of strategic initiatives that strengthen our foundation for long-term growth,” said Kevin Sayer, Dexcom’s chairman, president and CEO.

  ** PBF Energy is projected to report quarterly earnings at $0.26 per share on revenue of $8.24 billion. ** Merck & Co is estimated to report quarterly earnings at $1.83 per share on revenue of $14.68 billion. ** Smith & Nephew is estimated to report earnings for its first quarter. ** Domino's Pizza is estimated to report quarterly earnings at $3.05 per share on revenue of $1.03 billion.

DexCom is set to give its latest quarterly earnings report on Thursday, 2022-04-28. Analysts estimate that DexCom will report an earnings per share of $0.52. DexCom bulls will hope to hear the company to announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

Insulet Highlights New Data For Omnipod 5 System For Type 1, Type 2 Diabetes

SAN DIEGO---- DexCom, Inc. (DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, will showcase for the first time its new global portfolio of real-time continuous glucose monitoring systems at the 15th International Conference on Advanced Technologies and Treatments for Diabetes held April 27-30, 2022 in Barcelona.

The S&P 500 traded lower for the third week in a row as investors brace for a potential 0.5% interest rate hike by the Federal Reserve. U.S. indices traded sharply lower Friday on continued weakness following comments from Federal Reserve Chair Powell suggesting a rate hike of 50 basis points is possible for May. The Fed has indicated it may move quicker on rate hikes to curb inflation.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

DexCom, Inc. (DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, today released its third annual Sustainability Report. “At Dexcom (DXCM), we remain focused on how we can better serve our stakeholders, including customers, employees, caregivers, investors, and communities,” said Kevin Sayer, chairman, president and CEO of Dexcom.

DexCom has outperformed the market over the past 5 years by 32.15% on an annualized basis producing an average annual return of 45.92%. Currently, DexCom has a market capitalization of $49.71 billion. Buying $100 In DXCM: If an investor had bought $100 of DXCM stock 5 years ago, it would be worth $652.97 today based on a price of $510.43 for DXCM at the time of writing.

On the heels of the latest NICE guidelines, Dexcom ONE is in review by NHS England for addition to the Drug Tariff DexCom, Inc. (DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the new Dexcom ONE Continuous Glucose Monitoring System will launch in the United Kingdom this May. The Dexcom ONE system is an easy-to-use real-time CGM that will b...